Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633686 | 0.78 | ALDH1A1 (0.46) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL26613912 | 0.78 | ALDH1A1 (0.46) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL35210968 | 0.78 | ROCK1 (0.34) | ROCK1 | |
| SCHEMBL30633793 | 0.75 | AAK1 (0.33) | — | |
| SCHEMBL35211173 | 0.75 | ROCK1 (0.33) | KDM4EROCK1 | |
| SCHEMBL35210583 | 0.73 | NR4A2 (0.39) | KDM4EALDH1A1ROCK1 | |
| SCHEMBL515152 | 0.71 | ROCK1 (0.40) | ROCK1 | |
| SCHEMBL30633689 | 0.70 | AKR1B1 (0.37) | ALDH1A1ROCK1 | |
| SCHEMBL31257632 | 0.69 | LPL (0.31) | — | |
| SCHEMBL35210560 | 0.69 | ROCK1 (0.34) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136586-A1 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | BEIGENE, LTD. (KY) | 2025-05-01 | — | — | US | disclosed |
| EP-4514797-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023208172-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136586-A1 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | CDK4, CDK7, CDK8 | KDM4E 527/4885ALDH1A1 2255/4885CYP1A2 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.